Fig. 5: Safety evaluation of MTX withdrawal. | npj Vaccines

Fig. 5: Safety evaluation of MTX withdrawal.

From: Beneficial effect of temporary methotrexate interruption on B and T cell responses upon SARS-CoV-2 vaccination in patients with rheumatoid arthritis or psoriatic arthritis

Fig. 5

a Increment of disease activity score in 28 joints using CRP between first and second visit (ΔDAS28-CRP) in MTX-m (n = 72), MTX-1ww (n = 71) and MTX-2ww (n = 73). b Increment of disability measured by the Health Assessment Questionnaire (ΔHAQ) in MTX-m (n = 72), MTX-1ww (n = 71) and MTX-2ww (n = 73). HAQ = 0 indicates no disability while a score of 3 indicates maximum disability. c Percentage of patients who relapsed during the study and severity of the relapse according to physician criteria. d Percentage of patients who relapsed during the study and severity of the relapse according to DAS28 criteria. Kruskal Wallis tests a, b or Fisher exact tests c, d were performed to assess statistical significance. The median of days between first and second visits was 77 (60–103) and the second visit took place a median of 29 days (28–35) after complete vaccination. Box plots represent the interquartile ranges, horizontal lines indicate the medians, and error bars extend to the upper and lower adjacent values.

Back to article page